GILEAD SCIENCES SL
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Expanded Access for IMMU-132
- Conditions
- Metastatic Triple-Negative Breast Carcinoma
- First Posted Date
- 2020-03-25
- Last Posted Date
- 2021-08-19
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT04320693
Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy
- Conditions
- Metastatic Solid Tumor
- Interventions
- Drug: Sacituzumab Govitecan-hiy
- First Posted Date
- 2020-03-24
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 25
- Registration Number
- NCT04319198
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)
- Conditions
- Myelodysplastic Syndromes
- Interventions
- First Posted Date
- 2020-03-18
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 539
- Registration Number
- NCT04313881
- Locations
- 🇺🇸
Thomas Jefferson University, Sidney Kimmel Cancer Center; Clinical Research Organization, Philadelphia, Pennsylvania, United States
🇺🇸Swedish Cancer Institute, Seattle, Washington, United States
🇺🇸Winship Cancer Institute, Atlanta, Georgia, United States
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment
- First Posted Date
- 2020-03-03
- Last Posted Date
- 2021-01-26
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 1113
- Registration Number
- NCT04292730
- Locations
- 🇺🇸
Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave., Los Angeles, California, United States
🇺🇸Robert Wood Johnson University Hospital Somerset, 1 RWJ Place, New Brunswick, New Jersey, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)
- First Posted Date
- 2020-03-03
- Last Posted Date
- 2020-12-31
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 4891
- Registration Number
- NCT04292899
- Locations
- 🇺🇸
UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 5201 Harry Hines Blvd., Dallas, Texas, United States
🇺🇸Prisma Health Richland Hospital, Columbia, South Carolina, United States
🇺🇸Alta Bates Summit Medical Center, Berkeley, California, United States
Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir (SOF/VEL) Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX ) FDC for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection
- First Posted Date
- 2019-12-26
- Last Posted Date
- 2021-10-27
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 87
- Registration Number
- NCT04211909
- Locations
- 🇰🇷
Gachon University Gil Medical Center, Incheon, Korea, Republic of
🇰🇷The Catholic University of Korea, Seoul Saint Mary's Hospital, Seoul, Korea, Republic of
🇰🇷Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-D, Korea, Republic of
Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance
- Conditions
- HIV-1-infection
- Interventions
- Drug: Failing ARV RegimenDrug: Optimized Background Regimen (OBR)
- First Posted Date
- 2019-11-04
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 72
- Registration Number
- NCT04150068
- Locations
- 🇺🇸
Mills Clinical Research, Los Angeles, California, United States
🇺🇸Emory Hospital Midtown Infectious Disease Clinic, Atlanta, Georgia, United States
🇺🇸North Texas Infectious Diseases Consultants, P.A., Dallas, Texas, United States
Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIV
- Conditions
- HIV-1-infection
- Interventions
- First Posted Date
- 2019-10-29
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 183
- Registration Number
- NCT04143594
- Locations
- 🇺🇸
Howard Brown Health Center, Chicago, Illinois, United States
🇺🇸Northstar Healthcare, Chicago, Illinois, United States
🇺🇸Case Clinical Research Site/University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Study to Evaluate the Efficacy and Safety of Tilpisertib in Adults With Moderately to Severely Active Ulcerative Colitis
- First Posted Date
- 2019-10-18
- Last Posted Date
- 2022-08-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 19
- Registration Number
- NCT04130919
- Locations
- 🇺🇸
Alliance Medical Research, Coral Springs, Florida, United States
🇺🇸Encore Borland-Groover Clinical Research, Jacksonville, Florida, United States
🇺🇸Allegiance Research Specialists, LLC, Wauwatosa, Wisconsin, United States
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy
- Conditions
- Psoriatic Arthritis
- Interventions
- First Posted Date
- 2019-10-04
- Last Posted Date
- 2022-03-18
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 106
- Registration Number
- NCT04115839
- Locations
- 🇨🇦
G.R.M.O. (Groupe de recherche en maladies osseuses) Inc., Quebec, Canada
🇯🇵Keio University Hospital, Tokyo, Japan
🇵🇱Synexus Polska Sp. z o.o. Oddzial w Katowicach, Katowice, Poland